Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

NCT ID: NCT00725387

Last Updated: 2019-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

214 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-08-31

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than 18-year-old, diagnosed with cancer
* Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them

Exclusion Criteria

* Patients who cannot complete a PET/CT scan
* Pregnant women
* Healthy volunteers
* Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanford University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrei Iagaru M.D

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford University School of Medicine

Stanford, California, United States

Site Status

Aalborg Hospital

Aalborg, , Denmark

Site Status

Apollo Hospital

Chennai, , India

Site Status

Coimbra University Hospital

Coimbra, , Portugal

Site Status

Pretoria Academic Hospital

Pretoria, , South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Denmark India Portugal South Africa

References

Explore related publications, articles, or registry entries linked to this study.

Iagaru A, Mittra E, Mosci C, Dick DW, Sathekge M, Prakash V, Iyer V, Lapa P, Isidoro J, de Lima JM, Gambhir SS. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med. 2013 Feb;54(2):176-83. doi: 10.2967/jnumed.112.108803. Epub 2012 Dec 14.

Reference Type DERIVED
PMID: 23243299 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

98043

Identifier Type: OTHER

Identifier Source: secondary_id

SU-07232008-1266

Identifier Type: OTHER

Identifier Source: secondary_id

VAR0024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

18F-NaF PET Imaging for Bone Scintigraphy
NCT01930812 COMPLETED PHASE3
18-F-Fluoroacetate as PET Imaging Agent
NCT01320787 WITHDRAWN PHASE1